ArticleNeuropathology : official journal of the Japanese Society of Neuropathology2026
Elevated Expression of Caveolin-1 Reflects a Poor Prognosis in Patients With Primary Central Nervous System Lymphomas.
Article in Neuropathology : official journal of the Japanese Society of Neuropathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Caveolin-1 (Cav-1) is a component of the vesicle-like structure of the plasma membrane called caveolae. Cav-1 is involved in the transport of substances from the plasma membrane to the intracellular space of various cells. It has been reported that it is involved in the growth mechanisms, angiogenesis, and immune evasion of various malignant tumors. In the present study, the relationships between Cav-1 expression in primary central nervous system lymphomas (PCNSLs) and clinicopathological characteristics were investigated to clarify the role of Cav-1 in the progression of PCNSLs and patient prognosis. The expression of Cav-1 was assessed in 39 PCNSLs (CNS diffuse large B-cell lymphomas) using immunostaining, and its prognostic significance was evaluated. Cav-1 expression by PCNSLs was evaluated using the histoscore (H-score). The H-score for Cav-1 in PCNSLs ranged from 0 to 90 (median 20); there were 12 cases showing no score (H-score 0), 11 cases with a low score (0 < H-score < 20), and 16 cases with a high score (H-score ≥ 20). Survival was significantly lower in patients with high H-scores than in those with no score and low H-scores (p < 0.01), and in patients with high numbers of Cav-1-positive vessels than in those with low numbers of Cav-1-positive vessels (p < 0.05). Cav-1 positivity in tumor cells was correlated with the Ki-67 labeling index and the number of Cav-1-positive vessels. These results suggest that Cav-1 may be involved in the proliferation and angiogenesis of PCNSL cells. The present study also demonstrated that overexpression of Cav-1 in PCNSLs is associated with tumor progression and a poor patient prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.